metarrestin Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1 (1)

Interventional (1)

National Cancer Institute (NCI) (1)

No (1)

No (1)

Adult (18+) (1)
Pediatric (Under 18) (1)

I am/have/had

I am/have/hadx-rays

I am/have/hadrenal function test

I am/have/hadprimary tumor

I am/have/hadblood tests

I am/have/hadpancreatic cancer

I am/have/hadMRI

I am/have/hadsystemic chemotherapy

I am/have/hadcancer

I am/have/hadelectrocardiogram

I am/have/hadblood test

I am/have/hadsolid tumor

I am/have/hadmetastasis

I am/have/hadblood transfusion

I am/have/hadneutrophil count

I am/have/hadgilbert's syndrome

I am/have/hadplatelet count

I am/have/hadct scan

I am/have/hadbreast cancer

I am/have/hadinherited long qt syndrome

I am/have/hadelectroencephalogram

added new label for I am/have/had

more

I am looking for

I am looking forx-rays

I am looking forpediatric

I am looking formetarrestin

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For pediatric ages
For Seniors
Recruiting in 10s
Interventional Study
all
Recruiting

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Objective To find a safe dose of metarrestin and to see if this dose shrinks tumors. Eligibility Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies.

x-rays

renal function test

primary tumor

blood tests

pancreatic cancer

0 views
16 Feb, 2024
1 location

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.